You are here

JPMHC 2021

J.P. Morgan: Will Biotech’s Virtual 2021 Launch Become the New Reality?

J.P. Morgan: Will Biotech’s Virtual 2021 Launch Become the New Reality?

BioSpace

virtual meetings

Flag link:

JPM: 'Stick a fork in it'—J.P. Morgan in San Francisco is done, reader poll results say

JPM: 'Stick a fork in it'—J.P. Morgan in San Francisco is done, reader poll results say

Fierce Pharma

virtual meetings

Flag link:

Final Highlights from the 2021 J.P. Morgan Healthcare Conference

Final Highlights from the 2021 J.P. Morgan Healthcare Conference

BioSpace

intravenous immunoglobulin

IDEAYA Biosciences

Jounce Therapeutics

Puma Biotechnology

Flag link:

JPM: Established relationships were key to pandemic drug launches, Incyte CEO says

JPM: Established relationships were key to pandemic drug launches, Incyte CEO says

Fierce Pharma

Flag link:

Intuitive, J&J, Medtronic and Zimmer talk robotic surgery ambitions: JPM21

Intuitive, J&J, Medtronic and Zimmer talk robotic surgery ambitions: JPM21

Medtech Dive

robotic surgery

Intuitive Surgical

Flag link:

JPM: Jazz eyes a 'dramatic' shift to new-drug revenue by 2022, CEO says

JPM: Jazz eyes a 'dramatic' shift to new-drug revenue by 2022, CEO says

Fierce Pharma

Jazz Pharmaceuticals

Flag link:

#JPM21: Avidity CSO Art Levin runs full speed to the clinic with 'dream' antibody oligonucleotide conjugate therapy

#JPM21: Avidity CSO Art Levin runs full speed to the clinic with 'dream' antibody oligonucleotide conjugate therapy

Endpoints

oligonucleotide-based therapies

muscle diseases

Flag link:

JPM: How did Pfizer up its COVID-19 vaccine capacity? 'Out of the box manufacturing,' CEO says

JPM: How did Pfizer up its COVID-19 vaccine capacity? 'Out of the box manufacturing,' CEO says

Fierce Pharma

drug manufacturing

Flag link:

JPM: Sanofi's new chief digital officer steps up ambitions in marketing, research and even e-commerce

JPM: Sanofi's new chief digital officer steps up ambitions in marketing, research and even e-commerce

Fierce Pharma

Flag link:

JPM: CureVac's new pharma partner Bayer says its COVID-19 vaccine not just an also-ran

JPM: CureVac's new pharma partner Bayer says its COVID-19 vaccine not just an also-ran

Fierce Biotech

Flag link:

A longtime Pfizer chief's ultra-quiet biotech re-emerges with new cash and plans for the clinic

A longtime Pfizer chief's ultra-quiet biotech re-emerges with new cash and plans for the clinic

Endpoints

Elucida Oncology

Flag link:

JPM: Lilly, Moderna, insitro CEOs say pandemic forced R&D, marketing and ops changes worth keeping

JPM: Lilly, Moderna, insitro CEOs say pandemic forced R&D, marketing and ops changes worth keeping

Fierce Pharma

Stephane Bancel

Flag link:

JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business

JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business

BioPharma Dive

Flag link:

JPM Week: Will the first COVID-19 vaccines deter future launches? Not at all, experts say

JPM Week: Will the first COVID-19 vaccines deter future launches? Not at all, experts say

Fierce Pharma

Flag link:

JPM: Verve Therapeutics unveils its lead program—a one-and-done treatment for genetic high cholesterol

JPM: Verve Therapeutics unveils its lead program—a one-and-done treatment for genetic high cholesterol

Fierce Biotech

Verve Therapeutics

familial hypercholesterolemia

Flag link:

Key takeaways from BioNTech CEO’s JPM presentation

Key takeaways from BioNTech CEO’s JPM presentation

MedCity News

Flag link:

JPM: Novartis CMO Tsai on how the pandemic is changing the face of biopharma R&D, how pharma works

JPM: Novartis CMO Tsai on how the pandemic is changing the face of biopharma R&D, how pharma works

Fierce Biotech

Flag link:

JPM: Boehringer inks Enara deal to source 'dark antigens' for cancer immunotherapies

JPM: Boehringer inks Enara deal to source 'dark antigens' for cancer immunotherapies

Fierce Biotech

Boehringer Ingelheim

cancer vaccines

Flag link:

JPM: 'Very soon,' says Johnson & Johnson CEO as world waits for its COVID-19 vaccine data

JPM: 'Very soon,' says Johnson & Johnson CEO as world waits for its COVID-19 vaccine data

Fierce Pharma

clinical trials

Flag link:

JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining

JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining

BioPharma Dive

Vertex Pharmaceuticals

Sarepta Therapeutics

Flag link:

Pages